Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party
about
How I treat acquired aplastic anemiaHaploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemiaNew directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunityAlternative donor transplant of benign primary hematologic disordersBone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.Successful autologous cord blood transplantation in a child with acquired severe aplastic anemiaRecent advances in treatment of aplastic anemia.Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials NeFirst-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapyClinical management of aplastic anemia.Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysisBlood and marrow transplant clinical trials network state of the Science Symposium 2014Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant researchEvolving hematopoietic stem cell transplantation strategies in severe aplastic anemia.Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation studyFludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party.Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.The Third Consensus Conference on the treatment of aplastic anemia.Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches.How I manage aplastic anaemia in children.Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression.Management of acquired aplastic anemia in children.Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation.New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.Aplastic anemia: possible associations with lymphoproliferative neoplasms.Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations.Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience.Incidence and outcome of acquired aplastic anemia-real-world data from patients diagnosed in Sweden from 2000-2011.Current management of severe acquired aplastic anemia.Combination antifungal therapy and surgery for the treatment of invasive pulmonary aspergillosis after hematopoietic stem cell transplantation.Hematopoietic SCT in Iranian children 1991-2012.Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning?Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia.
P2860
Q24617687-54811170-12D0-4389-97C6-EE4FC8477800Q26799396-C00C7862-4BE8-4AFD-AFD2-C41E12A96806Q26823090-296F92E6-43F6-4862-97D4-52704FA03F4CQ26823398-7EFA89C7-CB38-4FF4-ADD3-F6BD55BE90AEQ30249748-0EE7E725-9ABB-43EE-98DD-3FC2A43992EEQ34241314-7BA2B27E-07BA-49CB-9269-C5C47827F1EBQ34451351-AAEC6267-9CAA-40C3-8435-19FE291D1D7AQ34645147-B8004AAD-09A1-4D6A-914D-F465144DE644Q34649082-34D92870-D842-48CC-A570-21E7835EA8AEQ35112372-06110FF3-DAED-480A-AD82-30821846C126Q35571068-427061D2-8DFF-4DB0-A94E-327B398F3BEBQ35591760-86AFC9EF-51D8-49D8-B82E-D99179FDB3F3Q36055158-33CDFEFB-3732-4313-A104-C1D520AFCC60Q36395151-3ECD86F0-588C-4085-BD36-CDADAD6F93CEQ36497220-D4B9B2C9-AF4A-47C1-9604-42BC8A63D8ECQ36577708-A714BD4E-9343-40EF-B0B9-DBD96FC24035Q36806501-9941653D-C1D5-46A2-9B04-AA52AF8927FFQ36884109-C088B1A9-1BFA-4A67-9E6E-D686F61B11D9Q36916440-51D41DFC-7A04-405F-8AD2-158D8487888BQ37216480-F48F1DCB-E384-48C7-8D84-4CCE6949DBEBQ37600436-A82DEB03-8DFC-491E-9749-3258DF96B35FQ37880645-2A806146-9C77-44E0-B679-D0C25ED99ADAQ37884078-89053F7F-D7E3-4367-A77D-998CD56D3B8AQ37986162-61C7A124-B9AD-4C38-8157-B3B9268BB716Q38062303-5E4CC4AF-9FA8-443B-85BF-28256E5650BFQ38071931-2DB9DD6F-DB10-4135-986C-780D54CC25E9Q38103184-FE6112F2-C36A-4EEC-9033-9A45ED42E7B0Q38155240-7E6DA165-A76C-4A5F-A9AF-59D7296747B7Q38160780-03249DDF-6F9F-4153-ADC9-7DCAD4375DCEQ38205956-DD0339B0-7E44-4E80-A0B0-382298875F3FQ38261555-934D0DAF-D063-4166-83F5-35893CF3C565Q38520096-11104FA2-5E57-4213-83BB-210A6B816C5FQ38636146-FCFCED6F-6702-4011-BE17-D60C5BE00845Q38656500-78C38229-3EA7-4BC9-8C54-6F47410190E7Q38694686-EFFC39D4-1901-476B-AF3A-2E58CA475322Q38926091-F27F2A26-33F5-4564-880B-546E3C678F8FQ39054767-49BA2579-AC20-45C0-B53C-09345C7C478EQ39972680-431ADC83-B8CB-4429-94C8-F62229737EC8Q40104076-CD44CA96-F860-4AA1-A1D7-53BE70CE1FE9Q40298403-AA17C82F-FA23-4E7E-98F2-1304E57D4267
P2860
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@ast
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@en
type
label
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@ast
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@en
prefLabel
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@ast
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@en
P2093
P2860
P50
P1433
P1476
Fludarabine, cyclophosphamide, ...... rom the EBMT-SAA Working Party
@en
P2093
Andrea Bacigalupo
Anna Locasciulli
Arcangelo Prete
Avichai Shimoni
Gerard Socie'
Jacob Passweg
Judith Marsh
Maria Teresa Van Lint
Mats Brune
Rosi Oneto
P2860
P304
P356
10.3324/HAEMATOL.2009.018267
P577
2010-05-21T00:00:00Z